Quick Answer
Protagonist Therapeutics, Inc reported Stockholders Equity of $614.71 million for the year ending 2025.
- Protagonist Therapeutics, Inc showed a decrease of -9.0% in Stockholders Equity from 2024 to 2025.
- This data is from Protagonist Therapeutics, Inc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $97.49 million | Q1 2017: $74.89 million | Q2 2017: $61.03 million | Q3 2017: $57.84 million | Q1 2018: $114.62 million | Q2 2018: $107.66 million | Q3 2018: $123.96 million | Q1 2019: $100.83 million | Q2 2019: $84.32 million | Q3 2019: $95.36 million | Q1 2020: $62.67 million | Q2 2020: $167.49 million | Q3 2020: $169.59 million | Q1 2021: $259.33 million | Q2 2021: $357.45 million | Q3 2021: $329.66 million | Q1 2022: $301.78 million | Q2 2022: $267.98 million | Q3 2022: $243.62 million | Q1 2023: $216.17 million | Q2 2023: $294.07 million | Q3 2023: $302.15 million | Q1 2024: $560.44 million | Q2 2024: $541.32 million | Q3 2024: $531.92 million | Q1 2025: $689.05 million | Q2 2025: $668.02 million | Q3 2025: $645.44 million.
- Over the full 13 years of available data (2013 to 2025), Protagonist Therapeutics, Inc's Stockholders Equity has grown by 44,196.6%.
- Historical annual values: Fiscal year 2025: $614.71 million | Fiscal year 2024: $675.30 million | Fiscal year 2023: $336.68 million | Fiscal year 2022: $215.61 million | Fiscal year 2021: $300.02 million | Fiscal year 2020: $279.61 million | Fiscal year 2019: $79.96 million | Fiscal year 2018: $112.52 million | Fiscal year 2017: $120.63 million | Fiscal year 2016: $87.56 million | Fiscal year 2015: -$27.40 million | Fiscal year 2014: -$12.62 million | Fiscal year 2013: -$1.39 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: